Literature DB >> 33923641

Natural Compounds as Therapeutic Agents: The Case of Human Topoisomerase IB.

Alessio Ottaviani1, Federico Iacovelli1, Paola Fiorani1,2, Alessandro Desideri1.   

Abstract

Natural products are widely used as source for drugs development. An interesting example is represented by natural drugs developed against human topoisomerase IB, a ubiquitous enzyme involved in many cellular processes where several topological problems occur due the formation of supercoiled DNA. Human topoisomerase IB, involved in the solution of such problems relaxing the DNA cleaving and religating a single DNA strand, represents an important target in anticancer therapy. Several natural compounds inhibiting or poisoning this enzyme are under investigation as possible new drugs. This review summarizes the natural products that target human topoisomerase IB that may be used as the lead compounds to develop new anticancer drugs. Moreover, the natural compounds and their derivatives that are in clinical trial are also commented on.

Entities:  

Keywords:  cancer; natural products; topoisomerase

Year:  2021        PMID: 33923641     DOI: 10.3390/ijms22084138

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  3 in total

1.  Research Status and Hotspots of Anticancer Natural Products Based on the Patent Literature and Scientific Articles.

Authors:  Junkai Shen; Jiahuan Li; Peiming Yu; Gangjun Du
Journal:  Front Pharmacol       Date:  2022-06-17       Impact factor: 5.988

2.  Innovation through Tradition: The Current Challenges in Cancer Treatment.

Authors:  Luigi Sapio; Silvio Naviglio
Journal:  Int J Mol Sci       Date:  2022-05-10       Impact factor: 6.208

3.  From Antarctica to cancer research: a novel human DNA topoisomerase 1B inhibitor from Antarctic sponge Dendrilla antarctica.

Authors:  Alessio Ottaviani; Joshua Welsch; Keli Agama; Yves Pommier; Alessandro Desideri; Bill J Baker; Paola Fiorani
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.